Investors Event Calendar
Environmental, Social and Governance (ESG)
ESG Updates: July 22, 2021 (PDF 1.8 MB) | Apr 28, 2021 (PDF 0.3 MB) | Jan 27, 2021 (PDF 0.5 MB) | Oct 28, 2020 (PDF 0.5 MB)
Latest updates: Novartis Enterprise Risk Management (PDF 0.2 MB) | Materiality Assessments Webinars
We have created a set of environmental, social and governance indices to signpost where our key disclosures can be found across our publications and channels. Novartis aims to report comprehensively and transparently for all stakeholders concerned with ESG topics.
September 28, 2021
FDA grants Priority Review for investigational targeted radioligand therapy 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer (mCRPC)
September 03, 2021
Novartis announces discontinuation of CIRRUS-1 study of CFZ533 (iscalimab) in kidney transplant patients
Novartis COVID-19 Information Center
Investor Relations Contacts
For questions about investor relations or the share registry, please contact our team.